A L Solomon1, K W Siddals2, P N Baker3, J M Gibson2, J D Aplin1, M Westwood4. 1. Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9WL, UK; Maternal and Fetal Health Research Centre, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, UK. 2. Centre for Imaging Sciences, Institute of Population Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. 3. Gravida, University of Auckland, Auckland, New Zealand. 4. Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9WL, UK; Maternal and Fetal Health Research Centre, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, UK. Electronic address: melissa.westwood@manchester.ac.uk.
Abstract
BACKGROUND: Insulin-like growth factors (IGF) regulate fetal growth through their effects on placenta. Their actions are influenced by IGF binding protein-1. Phosphorylated IGFBP-1 (pIGFBP-1) has high affinity for IGF-I and usually inhibits IGF-I activity but during pregnancy, it is de-phosphorylated to generate lower affinity isoforms and consequently, increased IGF bioavailability. Here we investigate the role of placenta in this process. RESULTS: Our data show that term human placental explants, but not their conditioned medium, can de-phosphorylate IGFBP-1 through the action of placental alkaline phosphatase (PLAP). DISCUSSION: PLAP-mediated de-phosphorylation of IGFBP-1 may provide a mechanism for controlling IGF-I bioavailability and action at the maternal/fetal interface.
BACKGROUND: Insulin-like growth factors (IGF) regulate fetal growth through their effects on placenta. Their actions are influenced by IGF binding protein-1. Phosphorylated IGFBP-1 (pIGFBP-1) has high affinity for IGF-I and usually inhibits IGF-I activity but during pregnancy, it is de-phosphorylated to generate lower affinity isoforms and consequently, increased IGF bioavailability. Here we investigate the role of placenta in this process. RESULTS: Our data show that term human placental explants, but not their conditioned medium, can de-phosphorylate IGFBP-1 through the action of placental alkaline phosphatase (PLAP). DISCUSSION: PLAP-mediated de-phosphorylation of IGFBP-1 may provide a mechanism for controlling IGF-I bioavailability and action at the maternal/fetal interface.
Authors: Birgit Hirschmugl; Sarah Crozier; Nina Matthews; Eva Kitzinger; Ingeborg Klymiuk; Hazel M Inskip; Nicholas C Harvey; Cyrus Cooper; Colin P Sibley; Jocelyn Glazier; Christian Wadsack; Keith M Godfrey; Gernot Desoye; Rohan M Lewis Journal: Int J Obes (Lond) Date: 2018-06-13 Impact factor: 5.095
Authors: Nara R B Cônsolo; Jasper C Munro; Stéphanie L Bourgon; Niel A Karrow; Alan H Fredeen; Janel E Martell; Yuri R Montanholi Journal: Animals (Basel) Date: 2018-08-02 Impact factor: 2.752